{"pmid":32344425,"title":"The Doctor's Dilemma: lessons from GB Shaw in a modern pandemic COVID-19.","text":["The Doctor's Dilemma: lessons from GB Shaw in a modern pandemic COVID-19.","In the current COVID 19 pandemic, the only treatments are supportive as no definitive pharmacological intervention is available. The heterogeneity of the immune response in different patient groups is clear with less severe illness in children. Understanding these disparities is particularly important as severely affected patients with COVID19 cannot always be predicted before they experience a cytokine storm and multiorgan dysfunction. Over 100 years ago, the concept of individualised immunotherapy was introduced by Sir Almroth Wright and immortalised in GB Shaw's play The Doctor's Dilemma. Shaw's play The Doctor's Dilemma explores the issues of private medical practice, equality of health care delivery, rationing of scarce resources (intensive care) and high-risk therapies. The play also describes the dilemma of rationing of resources and selecting the correct patient for new experimental therapies. Immunological theories of the time are now reflected in current understanding of inflammatory responses in sepsis and immunomodulation during the COVID19 pandemic.","Pediatr Res","Molloy, Eleanor J","32344425"],"abstract":["In the current COVID 19 pandemic, the only treatments are supportive as no definitive pharmacological intervention is available. The heterogeneity of the immune response in different patient groups is clear with less severe illness in children. Understanding these disparities is particularly important as severely affected patients with COVID19 cannot always be predicted before they experience a cytokine storm and multiorgan dysfunction. Over 100 years ago, the concept of individualised immunotherapy was introduced by Sir Almroth Wright and immortalised in GB Shaw's play The Doctor's Dilemma. Shaw's play The Doctor's Dilemma explores the issues of private medical practice, equality of health care delivery, rationing of scarce resources (intensive care) and high-risk therapies. The play also describes the dilemma of rationing of resources and selecting the correct patient for new experimental therapies. Immunological theories of the time are now reflected in current understanding of inflammatory responses in sepsis and immunomodulation during the COVID19 pandemic."],"journal":"Pediatr Res","authors":["Molloy, Eleanor J"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344425","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41390-020-0927-1","topics":["Prevention"],"weight":1,"_version_":1666138495103533056,"score":9.490897,"similar":[{"pmid":32445581,"title":"COVID-19: Legal implications for critical care.","text":["COVID-19: Legal implications for critical care.","The COVID-19 pandemic has caused an unprecedented challenge for the provision of critical care. Anticipating an unsustainable burden on the health service, the UK government introduced numerous legislative measures culminating in the Coronavirus Act, which interfere with existing legislation and rights. However, the existing standards and legal frameworks relevant to critical care clinicians are not extinguished but anticipated to adapt to a new context. This new context influences the standard of care that can be reasonably provided and yields numerous human rights considerations, for example in the use of restraints or the restrictions placed upon patients and visitors under the Infection Prevention and Control guidance. The changing landscape, has also highlighted previously unrecognised legal dilemmas. The perceived difficulties in the provision of PPE for employees pose a legal risk for trusts and a regulatory risk for clinicians. The spectre of rationing critical care poses a number of legal issues. Notably, the flux between clinical decisions based on best interests towards decisions explicitly based on resource considerations should be underpinned by an authoritative public policy decision to preserve legitimacy and lawfulness. Such a policy should be medically coherent, legally robust and ethically justified. The current crisis yields numerous challenges for clinicians aspiring to remain faithful to medico-legal and human rights principles developed over many decades, especially when such considerations could easily be dismissed. However, it is exactly at such times that these principles are needed the most and clinicians play a disproportionate role in safeguarding such principles for the most vulnerable.","Anaesthesia","Coghlan, N","Archard, D","Sipanoun, P","Hayes, T","Baharlo, B","32445581"],"abstract":["The COVID-19 pandemic has caused an unprecedented challenge for the provision of critical care. Anticipating an unsustainable burden on the health service, the UK government introduced numerous legislative measures culminating in the Coronavirus Act, which interfere with existing legislation and rights. However, the existing standards and legal frameworks relevant to critical care clinicians are not extinguished but anticipated to adapt to a new context. This new context influences the standard of care that can be reasonably provided and yields numerous human rights considerations, for example in the use of restraints or the restrictions placed upon patients and visitors under the Infection Prevention and Control guidance. The changing landscape, has also highlighted previously unrecognised legal dilemmas. The perceived difficulties in the provision of PPE for employees pose a legal risk for trusts and a regulatory risk for clinicians. The spectre of rationing critical care poses a number of legal issues. Notably, the flux between clinical decisions based on best interests towards decisions explicitly based on resource considerations should be underpinned by an authoritative public policy decision to preserve legitimacy and lawfulness. Such a policy should be medically coherent, legally robust and ethically justified. The current crisis yields numerous challenges for clinicians aspiring to remain faithful to medico-legal and human rights principles developed over many decades, especially when such considerations could easily be dismissed. However, it is exactly at such times that these principles are needed the most and clinicians play a disproportionate role in safeguarding such principles for the most vulnerable."],"journal":"Anaesthesia","authors":["Coghlan, N","Archard, D","Sipanoun, P","Hayes, T","Baharlo, B"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445581","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/anae.15147","keywords":["covid-19","critical care","ethics","human rights","law","resource allocation"],"locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1667600475918172162,"score":168.59424},{"pmid":32321540,"pmcid":"PMC7175817","title":"COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.","text":["COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.","On March 11th, 2020 the World Health Organization declared COVID-19 a global pandemic. The infection, transmitted by 2019 novel coronavirus (2019-nCov), was first discovered in December 2019, in Wuhan, Hubei Province, and then rapidly spread worldwide. Italy was early and severely involved, with a critical spread of the infection and a very high number of victims. Person-to-person spread mainly occurs via respiratory droplets and contact. The median incubation period is 5 days. The spectrum of respiratory symptoms may range from mild to severe, strictly depending on the age of the patient and the underlying comorbidities.In children COVID-19 related disease is less frequent and less aggressive. In Italy 1% of positive cases are under 18 years of age, and no deaths have been recorded before 29 years of age. For patients affected by rheumatic disease, despite the concerns related to the imbalance of their immune response and the effect of immunosuppressive treatments, there are still few data to understand the real consequences of this infection. Major scientific societies have issued recommendations to help rheumatologists in caring their patients. Interestingly, some of the drugs mostly used by rheumatologists appear to be promising in critical COVID-19 infected patients, where the hyperinflammation and cytokine storm seem to drive to the multiorgan failure.Pediatric rheumatologists are expected to play a supporting role in this new front of COVID-19 pandemic, both as general pediatricians treating infected children, and as rheumatologists taking care of their rheumatic patients, as well as offering their experience in the possible alternative use of immunomodulatory drugs.","Pediatr Rheumatol Online J","Licciardi, Francesco","Giani, Teresa","Baldini, Letizia","Favalli, Ennio Giulio","Caporali, Roberto","Cimaz, Rolando","32321540"],"abstract":["On March 11th, 2020 the World Health Organization declared COVID-19 a global pandemic. The infection, transmitted by 2019 novel coronavirus (2019-nCov), was first discovered in December 2019, in Wuhan, Hubei Province, and then rapidly spread worldwide. Italy was early and severely involved, with a critical spread of the infection and a very high number of victims. Person-to-person spread mainly occurs via respiratory droplets and contact. The median incubation period is 5 days. The spectrum of respiratory symptoms may range from mild to severe, strictly depending on the age of the patient and the underlying comorbidities.In children COVID-19 related disease is less frequent and less aggressive. In Italy 1% of positive cases are under 18 years of age, and no deaths have been recorded before 29 years of age. For patients affected by rheumatic disease, despite the concerns related to the imbalance of their immune response and the effect of immunosuppressive treatments, there are still few data to understand the real consequences of this infection. Major scientific societies have issued recommendations to help rheumatologists in caring their patients. Interestingly, some of the drugs mostly used by rheumatologists appear to be promising in critical COVID-19 infected patients, where the hyperinflammation and cytokine storm seem to drive to the multiorgan failure.Pediatric rheumatologists are expected to play a supporting role in this new front of COVID-19 pandemic, both as general pediatricians treating infected children, and as rheumatologists taking care of their rheumatic patients, as well as offering their experience in the possible alternative use of immunomodulatory drugs."],"journal":"Pediatr Rheumatol Online J","authors":["Licciardi, Francesco","Giani, Teresa","Baldini, Letizia","Favalli, Ennio Giulio","Caporali, Roberto","Cimaz, Rolando"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321540","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s12969-020-00422-z","keywords":["2019-ncov","covid-19","children","italy","respiratory syndrome","sars-cov-2"],"locations":["Wuhan","Hubei","Italy","Italy","multiorgan"],"countries":["Italy","China"],"countries_codes":["ITA|Italy","CHN|China"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1666138493789667328,"score":155.71223},{"pmid":32478472,"title":"Patient care protocols and personal safety measures for health care professionals in cardiac catheterization rooms during the COVID-19 outbreak in the National Institute of Cardiology.","text":["Patient care protocols and personal safety measures for health care professionals in cardiac catheterization rooms during the COVID-19 outbreak in the National Institute of Cardiology.","The COVID-19 was first described in late 2019 that quickly became a pandemic affecting every health system as we know it. The high transmissibility among humans represents a well-known high burden of morbidity and mortality not only for cardiovascular patients but also for a higher risk between health care professionals that must deliver high-quality care to them in any scenario, and cardiac catheterization rooms are no exception. This creates a new dilemma, minimize exposure to patients and health care professionals to COVID-19 while maintaining high quality in cardiovascular therapeutics. In order to achieve this, several international recommendations on treatment algorithms modifications and in safety measures in the catheterization room have been published, always aiming to solve this dilemma in the best possible way. Hereby, we present a summary of the most recent treatment algorithms in the most important cardiovascular interventions (acute coronary syndromes, structural and congenital heart diseases) as well as specific safety measures with a step-by-step preparedness before and after any interventional procedure during COVID-19 outbreak. The objective of this document is to inform and to train health care professionals that works in cardiac catheterization rooms on the risks as well on the plan for containment, mitigation, and response to the global situation of COVID-19 infection in order to apply this in their own local work environments.","Catheter Cardiovasc Interv","Eid-Lidt, Guering","Farjat Pasos, Julio Ivan","32478472"],"abstract":["The COVID-19 was first described in late 2019 that quickly became a pandemic affecting every health system as we know it. The high transmissibility among humans represents a well-known high burden of morbidity and mortality not only for cardiovascular patients but also for a higher risk between health care professionals that must deliver high-quality care to them in any scenario, and cardiac catheterization rooms are no exception. This creates a new dilemma, minimize exposure to patients and health care professionals to COVID-19 while maintaining high quality in cardiovascular therapeutics. In order to achieve this, several international recommendations on treatment algorithms modifications and in safety measures in the catheterization room have been published, always aiming to solve this dilemma in the best possible way. Hereby, we present a summary of the most recent treatment algorithms in the most important cardiovascular interventions (acute coronary syndromes, structural and congenital heart diseases) as well as specific safety measures with a step-by-step preparedness before and after any interventional procedure during COVID-19 outbreak. The objective of this document is to inform and to train health care professionals that works in cardiac catheterization rooms on the risks as well on the plan for containment, mitigation, and response to the global situation of COVID-19 infection in order to apply this in their own local work environments."],"journal":"Catheter Cardiovasc Interv","authors":["Eid-Lidt, Guering","Farjat Pasos, Julio Ivan"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478472","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/ccd.28979","keywords":["acute coronary syndrome","cardiac catheterization","congenital heart defects","pandemics","valvular heart diseases"],"topics":["Prevention"],"weight":1,"_version_":1668437834995859456,"score":151.0439},{"pmid":32472459,"title":"Treatment algorithm for COVID-19: a multidisciplinary point of view.","text":["Treatment algorithm for COVID-19: a multidisciplinary point of view.","The novel coronavirus (Sars-CoV-2) pandemic has spread rapidly, from December to the end of March, to 185 countries, and there have been over 3,000,000 cases identified and over 200,000 deaths. For a proportion of hospitalized patients, death can occur within a few days, mainly for adult respiratory distress syndrome or multi-organ dysfunction syndrome. In these patients, clinical signs and symptoms, as well as laboratory abnormalities, suggest a cytokine storm syndrome in response to the viral infection. No current targeted treatment is yet available for COVID-19, an unknown disease up to 2 months ago, which challenges doctors and researchers to find new drugs or reallocate other treatments for these patients. Since the beginning of the COVID-19 outbreak, a growing body of information on diagnostic and therapeutic strategies has emerged, mainly based on preliminary experience on retrospective studies or small case series. Antivirals, antimalarials, corticosteroids, biotechnological and small molecules, convalescent plasma and anticoagulants are among the drugs proposed for the treatment or in tested for COVID-19. Given the complexity of this new condition, a multidisciplinary management seems to be the best approach. Sharing and integrating knowledge between specialists, to evaluate the correct timing and setting of every treatment, could greatly benefit our patients. We reviewed the literature, combining it with our experiences and our specialist knowledge, to propose a management algorithm, correlating the clinical features with laboratory and imaging findings to establish the right timing for each treatment.Key Points* Critically ill COVID-19 patients show signs of cytokine storm syndrome.* No current targeted therapy is available, but a lot of drugs are in tested.* A multidisciplinary approach is crucial to manage COVID-19.* Choosing the correct timing of treatment is of pivotal importance to avoid the most severe complications.","Clin Rheumatol","Galluccio, Felice","Ergonenc, Tolga","Garcia Martos, Alvaro","Allam, Abdallah El-Sayed","Perez-Herrero, Maria","Aguilar, Ricardo","Emmi, Giacomo","Spinicci, Michele","Terrancle Juan, Ignacio","Fajardo-Perez, Mario","32472459"],"abstract":["The novel coronavirus (Sars-CoV-2) pandemic has spread rapidly, from December to the end of March, to 185 countries, and there have been over 3,000,000 cases identified and over 200,000 deaths. For a proportion of hospitalized patients, death can occur within a few days, mainly for adult respiratory distress syndrome or multi-organ dysfunction syndrome. In these patients, clinical signs and symptoms, as well as laboratory abnormalities, suggest a cytokine storm syndrome in response to the viral infection. No current targeted treatment is yet available for COVID-19, an unknown disease up to 2 months ago, which challenges doctors and researchers to find new drugs or reallocate other treatments for these patients. Since the beginning of the COVID-19 outbreak, a growing body of information on diagnostic and therapeutic strategies has emerged, mainly based on preliminary experience on retrospective studies or small case series. Antivirals, antimalarials, corticosteroids, biotechnological and small molecules, convalescent plasma and anticoagulants are among the drugs proposed for the treatment or in tested for COVID-19. Given the complexity of this new condition, a multidisciplinary management seems to be the best approach. Sharing and integrating knowledge between specialists, to evaluate the correct timing and setting of every treatment, could greatly benefit our patients. We reviewed the literature, combining it with our experiences and our specialist knowledge, to propose a management algorithm, correlating the clinical features with laboratory and imaging findings to establish the right timing for each treatment.Key Points* Critically ill COVID-19 patients show signs of cytokine storm syndrome.* No current targeted therapy is available, but a lot of drugs are in tested.* A multidisciplinary approach is crucial to manage COVID-19.* Choosing the correct timing of treatment is of pivotal importance to avoid the most severe complications."],"journal":"Clin Rheumatol","authors":["Galluccio, Felice","Ergonenc, Tolga","Garcia Martos, Alvaro","Allam, Abdallah El-Sayed","Perez-Herrero, Maria","Aguilar, Ricardo","Emmi, Giacomo","Spinicci, Michele","Terrancle Juan, Ignacio","Fajardo-Perez, Mario"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472459","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s10067-020-05179-0","keywords":["algorithm","covid-19","management","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1668255193320390656,"score":148.3493},{"pmid":32499910,"pmcid":"PMC7256627","title":"SARS-CoV-2 pandemic in Italy: ethical and organizational considerations.","text":["SARS-CoV-2 pandemic in Italy: ethical and organizational considerations.","The current SARS-CoV-2 pandemic is still raging in Italy. The country is currently plagued by a huge burden of virusrelated cases and deaths. So far, the disease has highlighted a number of problems, some in common with other Countries and others peculiar to Italy which has suffered from a mortality rate higher than that observed in China and in most Countries in the world. The causes must be sought not only in the average age of the population (one of the oldest in the world), but also in the inconsistencies of the regional health systems (into which the National Health System is divided) and their delayed response, at least in some areas. Ethical issues emerged from the beginning, ranging from restrictions on freedom of movements and restrictions on personal privacy due to the lockdown, further to the dilemma for healthcare professionals to select people for ICU hospitalization in a shortage of beds in Intensive Care Unit (ICU). Organizational problems also emerged, although an official 2007 document from the Ministry of Health had planned not only what measures had to be taken during an epidemic caused by respiratory viruses, but also what had to be done in the inter-epidemic period (including the establishment of DPIs stocks and ventilators), vast areas of Italy were totally unprepared to cope with the disease, as a line of that document was not implemented. Since organizational problems can worsen (and even cause) ethical dilemmas, every effort should be made in the near future to prepare the health system to respond to a similar emergency in a joint, coherent, and homogeneous way across the Country, as planned in the 2007 document. In this perspective, Pulmonary Units and specialists can play a fundamental role in coping with the disease not only in hospitals, as intermediate care units, but also at a territorial level in an integrated network with GPs.","Multidiscip Respir Med","Nardini, Stefano","Sanguinetti, Claudio M","De Benedetto, Fernando","Baccarani, Claudio","Del Donno, Mario","Polverino, Mario","Annesi-Maesano, Isabella","32499910"],"abstract":["The current SARS-CoV-2 pandemic is still raging in Italy. The country is currently plagued by a huge burden of virusrelated cases and deaths. So far, the disease has highlighted a number of problems, some in common with other Countries and others peculiar to Italy which has suffered from a mortality rate higher than that observed in China and in most Countries in the world. The causes must be sought not only in the average age of the population (one of the oldest in the world), but also in the inconsistencies of the regional health systems (into which the National Health System is divided) and their delayed response, at least in some areas. Ethical issues emerged from the beginning, ranging from restrictions on freedom of movements and restrictions on personal privacy due to the lockdown, further to the dilemma for healthcare professionals to select people for ICU hospitalization in a shortage of beds in Intensive Care Unit (ICU). Organizational problems also emerged, although an official 2007 document from the Ministry of Health had planned not only what measures had to be taken during an epidemic caused by respiratory viruses, but also what had to be done in the inter-epidemic period (including the establishment of DPIs stocks and ventilators), vast areas of Italy were totally unprepared to cope with the disease, as a line of that document was not implemented. Since organizational problems can worsen (and even cause) ethical dilemmas, every effort should be made in the near future to prepare the health system to respond to a similar emergency in a joint, coherent, and homogeneous way across the Country, as planned in the 2007 document. In this perspective, Pulmonary Units and specialists can play a fundamental role in coping with the disease not only in hospitals, as intermediate care units, but also at a territorial level in an integrated network with GPs."],"journal":"Multidiscip Respir Med","authors":["Nardini, Stefano","Sanguinetti, Claudio M","De Benedetto, Fernando","Baccarani, Claudio","Del Donno, Mario","Polverino, Mario","Annesi-Maesano, Isabella"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32499910","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.4081/mrm.2020.672","keywords":["icu beds","sars-cov-2","ethical and organizational issues","intermediate respiratory care","mortality rate"],"locations":["Italy","Italy","China","Italy","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"weight":0,"_version_":1668804508931588096,"score":145.63158}]}